Table 2 Event rates of hospitalisation for HF, MACE and all-cause mortality according to second-line therapy
Heart failure hospitalisation | MACE | All-cause mortality | ||||
|---|---|---|---|---|---|---|
No events | Rate per 1000 py | No events | Rate per 1000 py | No events | Rate per 1000 py | |
DPP-4 inhibitors | 203 | 6.9 (6.0–7.9) | 398 | 13.5 (12.2–15.0) | 542 | 18.3 (16.8–19.9) |
GLP-1 receptor agonists | 151 | 5.9 (5.0–6.9) | 261 | 10.1 (8.9–11.4) | 285 | 11.0 (9.7–12.3) |
SGLT-2 inhibitors | 19 | 4.9 (3.0–7.7) | 36 | 9.3 (6.5–12.9) | 45 | 11.6 (8.5–15.5) |
Sulfonylurea | 94 | 5.5 (4.4–6.7) | 236 | 13.8 (12.1–15.7) | 330 | 19.2 (17.2–21.4) |
Insulin | 156 | 11.7 (9.9–13.7) | 265 | 19.9 (17.5–22.3) | 663 | 49.3 (45.6–53.2) |